FdaApplication
BLA 125736
Identifiers
- fda_app_no: BLA125736
Properties
| Property | Value |
|---|---|
| applicant_name | Celgene Corporation, a Bristol-Myers Squibb Company |
| application_type | BLA |
| approval_date | 2021-03-03 |
Revenue by product
ABECMA
| Period | Revenue |
|---|---|
| Q4 2025 | $101.0M |
| Q3 2025 | $137.0M |
| Q2 2025 | $87.0M |
| Q1 2025 | $103.0M |
| Q4 2024 | $105.0M |
| Q3 2024 | $124.0M |
| Q2 2024 | $95.0M |
| Q1 2024 | $82.0M |
| Q4 2023 | $100.0M |
| Q3 2023 | $93.0M |
| Q2 2023 | $132.0M |
| Q1 2023 | $147.0M |
| Q4 2022 | $125.0M |
| Q3 2022 | $107.0M |
| Q2 2022 | $89.0M |
| Q1 2022 | $67.0M |
| Q4 2021 | $69.0M |
| Q3 2021 | $71.0M |
| Q2 2021 | $24.0M |
| Q1 2021 | $0.0M |
| Q4 2020 | $0.0M |
| Q3 2020 | $0.0M |
| Q2 2020 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ABECMA | — | 300 to 510 X 10^6 CHIMERIC ANTIGEN RECEPTOR (CAR)-POSITIVE T CELLS | Suspension |
| ABECMA | — | 300 to 460 X 10^6 CHIMERIC ANTIGEN RECEPTOR (CAR)-POSITIVE T CELLS | Suspension |
2 products